Evaluation of Mineralocorticoid Receptor Antagonism on Changes in NT-proBNP Among Persons With HIV
Suman Srinivasa, Christopher deFilippi, Kathleen V Fitch, Sanjna Iyengar, Grace Shen, Tricia H Burdo, Allie R Walpert, Teressa S Thomas, Gail K Adler, Steven K Grinspoon, Suman Srinivasa, Christopher deFilippi, Kathleen V Fitch, Sanjna Iyengar, Grace Shen, Tricia H Burdo, Allie R Walpert, Teressa S Thomas, Gail K Adler, Steven K Grinspoon
Abstract
Subclinical myocardial dysfunction is prevalent among well-treated persons with HIV (PWH). We have previously demonstrated unique renin-angiotensin-aldosterone system physiology among PWH with metabolic dysregulation. Mineralocorticoid receptor blockade may be a targeted treatment strategy for subclinical heart disease in PWH. Forty-six PWH were randomized to receive either eplerenone 50 mg daily or placebo in a 6-month randomized, double-blinded, placebo-controlled trial. We assessed changes in N-terminal pro-B-type natriuretic peptide (NT-proBNP), a biomarker of cardiac stretch, under controlled posture and dietary conditions. The eplerenone- and placebo-treated groups demonstrated a long duration of HIV with good immunological control. NT-proBNP levels were similar between the groups at baseline (41.1 [20.2, 97.9] vs 48.9 [29.2, 65.4] ng/L, P = .80) and decreased significantly more in the eplerenone- vs placebo-treated groups after 6 months (change NT-proBNP -9.6 [-46.8, 0.3] vs -3.0 [-17.0, 39.9] ng/L, P = .02 for comparison of change between groups). Decreases in NT-proBNP were independent of changes in systolic and diastolic blood pressure, and related to decreases in high-sensitivity C-reactive protein (ρ = 0.32, P = .05) and inversely to increases in serum aldosterone (ρ = -0.33, P = .04) among all participants. Treatment with eplerenone for 6 months vs placebo significantly decreases NT-proBNP levels among PWH, independent of eplerenone's known blood pressure-lowering effects. Further studies should elucidate whether lowering NT-proBNP in this at-risk metabolic population with subclinical heart disease will offer cardioprotection.
Clinical trial registration: NCT01405456.
Keywords: HIV; NT-proBNP; eplerenone; renin-angiotensin-aldosterone system.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.
Figures
References
- Sinha A, Feinstein MJ. Immune dysregulation in myocardial fibrosis, steatosis, and heart failure: current insights from HIV and the general population. Curr HIV/AIDS Rep. 2021;18(1):63-72.
- Hsue PY, Hunt PW, Ho JE, et al. . Impact of HIV infection on diastolic function and left ventricular mass. Circ Heart Fail. 2010;3(1):132-139.
- Savvoulidis P, Butler J, Kalogeropoulos A. Cardiomyopathy and heart failure in patients with HIV infection. Can J Cardiol. 2019;35(3):299-309.
- Srinivasa S, Fitch KV, Wong K, et al. . RAAS activation is associated with visceral adiposity and insulin resistance among HIV-infected patients. J Clin Endocrinol Metab. 2015;100(8):2873-2882.
- Srinivasa S, Fitch KV, Wong K, et al. . Randomized, placebo-controlled trial to evaluate effects of eplerenone on metabolic and inflammatory indices in HIV. J Clin Endocrinol Metab. 2018;103(6):2376-2384.
- Oestreicher EM, Martinez-Vasquez D, Stone JR, et al. . Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. Circulation. 2003;108(20):2517-2523.
- Rao AD, Shah RV, Garg R, et al. . Aldosterone and myocardial extracellular matrix expansion in type 2 diabetes mellitus. Am J Cardiol. 2013;112(1):73-78.
- Rocha R, Stier CT Jr, Kifor I, et al. . Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000;141(10):3871-3878.
- Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol. 1995;269(4 Pt 1):E657-E662.
- Pitt B, Pfeffer MA, Assmann SF, et al. ; TOPCAT Investigators . Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383-1392.
- Pfeffer MA, Claggett B, Assmann SF, et al. . Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131(1):34-42.
- Shah AM, Claggett B, Sweitzer NK, et al. . Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circ Heart Fail. 2015;8(6):1052-1058.
- Deswal A, Richardson P, Bozkurt B, Mann DL. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail. 2011;17(8):634-642.
- Wang TJ, Larson MG, Levy D, et al. . Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350(7):655-663.
- McKie PM, Cataliotti A, Sangaralingham SJ, et al. . Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study. Mayo Clin Proc. 2011;86(12):1154-1160.
- Geng Z, Huang L, Song M, Song Y. N-terminal pro-brain natriuretic peptide and cardiovascular or all-cause mortality in the general population: a meta-analysis. Sci Rep. 2017;7:41504.
- Berg T, Zdunek D, Stalke J, et al. . N-terminal pro-B-type natriuretic peptide (NT-proBNP) in HIV-1 infected individuals on HAART. Eur J Med Res. 2007;12(4):152-160.
- Mansoor A, Althoff K, Gange S, et al. . Elevated NT-pro-BNP levels are associated with comorbidities among HIV-infected women. AIDS Res Hum Retroviruses. 2009;25(10):997-1004.
- Holloway CJ, Ntusi N, Suttie J, et al. . Comprehensive cardiac magnetic resonance imaging and spectroscopy reveal a high burden of myocardial disease in HIV patients. Circulation. 2013;128(8):814-822.
- Liu CY, Heckbert SR, Lai S, et al. . Association of elevated NT-proBNP with myocardial fibrosis in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol. 2017;70(25):3102-3109.
- Mitchell A, Misialek JR, Folsom AR, et al. . Usefulness of N-terminal Pro-brain natriuretic peptide and myocardial perfusion in asymptomatic adults (from the Multi-Ethnic Study of Atherosclerosis). Am J Cardiol. 2015;115(10):1341-1345.
- Daniels LB, Clopton P, deFilippi CR, et al. . Serial measurement of N-terminal pro-B-type natriuretic peptide and cardiac troponin T for cardiovascular disease risk assessment in the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J. 2015;170(6):1170-1183.
- Hunt PW, Sinclair E, Rodriguez B, et al. . Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis. 2014;210(8):1228-1238.
- Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506-2512.
- Freiberg MS, Chang CC, Kuller LH, et al. . HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173(8):614-622.
- Eckard AR, Jiang Y, Debanne SM, Funderburg NT, McComsey GA. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis. 2014;209(8):1156-1164.
- Funderburg NT, Jiang Y, Debanne SM, et al. . Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infect Dis. 2014;58(4):588-595.
- Dirajlal-Fargo S, Kinley B, Jiang Y, et al. . Statin therapy decreases N-terminal pro-B-type natriuretic peptide in HIV: randomized placebo-controlled trial. Aids. 2015;29(3):313-321.
- Gottlieb GS, Sow PS, Hawes SE, et al. . Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. J Infect Dis. 2002;185(7):905-914.
- Martinez-Steele E, Awasana AA, Corrah T, et al. . Is HIV-2- induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic. Aids. 2007;21(3):317-324.
- Cardoso JS, Miranda AM, Moura B, et al. . Cardiac morbidity in the human immunodeficiency virus infection. Rev Port Cardiol. 1994;13(12):901-911.
Source: PubMed